Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shen Qi Tiao Shen prescription is a Traditional Chinese Medicine (TCM) herbal formula developed by The First Affiliated Hospital of Anhui University of Chinese Medicine. It is a component of the Xin'an Guben Peiyuan formula series, which is based on the Xin'an medical school's therapeutic principle of "strengthening the foundation and cultivating the source" (Guben Peiyuan). This specific prescription is designed to "regulate the kidney" (Tiao Shen) and is primarily investigated as an adjunctive therapy for patients with stable chronic obstructive pulmonary disease (COPD). In clinical studies, it is evaluated for its ability to improve lung function, reduce acute exacerbations, and enhance the quality of life when added to standard-of-care bronchodilators such as tiotropium. The formula typically contains botanical extracts known for their immunomodulatory and anti-inflammatory properties, such as *Astragalus membranaceus* (Huangqi) and *Panax ginseng* or *Codonopsis pilosula* (Shen).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Shen Qi Tiao Shen prescription.